JP2021518340A5 - - Google Patents

Info

Publication number
JP2021518340A5
JP2021518340A5 JP2020548963A JP2020548963A JP2021518340A5 JP 2021518340 A5 JP2021518340 A5 JP 2021518340A5 JP 2020548963 A JP2020548963 A JP 2020548963A JP 2020548963 A JP2020548963 A JP 2020548963A JP 2021518340 A5 JP2021518340 A5 JP 2021518340A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
halo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548963A
Other languages
English (en)
Japanese (ja)
Other versions
JP7453916B2 (ja
JP2021518340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021995 external-priority patent/WO2019178191A1/en
Publication of JP2021518340A publication Critical patent/JP2021518340A/ja
Publication of JP2021518340A5 publication Critical patent/JP2021518340A5/ja
Application granted granted Critical
Publication of JP7453916B2 publication Critical patent/JP7453916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548963A 2018-03-14 2019-03-13 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グリコピラノシダーゼ阻害剤 Active JP7453916B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862642932P 2018-03-14 2018-03-14
US62/642,932 2018-03-14
US201862690536P 2018-06-27 2018-06-27
US62/690,536 2018-06-27
US201862699443P 2018-07-17 2018-07-17
US62/699,443 2018-07-17
PCT/US2019/021995 WO2019178191A1 (en) 2018-03-14 2019-03-13 O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors

Publications (3)

Publication Number Publication Date
JP2021518340A JP2021518340A (ja) 2021-08-02
JP2021518340A5 true JP2021518340A5 (cg-RX-API-DMAC10.html) 2022-03-22
JP7453916B2 JP7453916B2 (ja) 2024-03-21

Family

ID=65952097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020548963A Active JP7453916B2 (ja) 2018-03-14 2019-03-13 O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グリコピラノシダーゼ阻害剤

Country Status (10)

Country Link
US (1) US20230117898A1 (cg-RX-API-DMAC10.html)
EP (2) EP3765458B1 (cg-RX-API-DMAC10.html)
JP (1) JP7453916B2 (cg-RX-API-DMAC10.html)
CN (2) CN118955490A (cg-RX-API-DMAC10.html)
AU (1) AU2019234759C1 (cg-RX-API-DMAC10.html)
CA (1) CA3093315A1 (cg-RX-API-DMAC10.html)
ES (1) ES2942211T3 (cg-RX-API-DMAC10.html)
MA (1) MA52004A (cg-RX-API-DMAC10.html)
MX (1) MX2020009530A (cg-RX-API-DMAC10.html)
WO (1) WO2019178191A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018223192A1 (en) * 2017-02-27 2019-06-20 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
KR20220118484A (ko) 2019-12-18 2022-08-25 얀센 파마슈티카 엔.브이. Oga 억제제 화합물
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AU2020409728A1 (en) 2019-12-18 2022-08-11 Janssen Pharmaceutica Nv OGA inhibitor compounds
KR102533471B1 (ko) 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
CN114213315A (zh) * 2021-12-31 2022-03-22 上海陶术生物科技有限公司 含氮杂环类化合物及其中间体的合成方法
CN114560805B (zh) * 2022-01-20 2024-11-29 上海陶术生物科技有限公司 含氮杂环化合物及其中间体的合成方法
CN121405694A (zh) * 2024-07-26 2026-01-27 浙江同源康医药股份有限公司 Oga抑制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2017106254A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
EP3555094A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
AU2018223192A1 (en) * 2017-02-27 2019-06-20 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors

Similar Documents

Publication Publication Date Title
JP2022500472A5 (cg-RX-API-DMAC10.html)
CA2662305A1 (en) Heterocyclic gpr40 modulators
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
JP2022550640A5 (cg-RX-API-DMAC10.html)
JP2014503528A5 (cg-RX-API-DMAC10.html)
JP2019506430A5 (cg-RX-API-DMAC10.html)
JP2010506854A5 (cg-RX-API-DMAC10.html)
AR066120A1 (es) Derivados de pirimidinona y sus metodos de uso
IL300298A (en) Apol1 inhibitors and methods of using the same
HRP20161177T1 (hr) Modulator glukagonskog receptora
JP2022552445A5 (cg-RX-API-DMAC10.html)
JP2022510925A5 (cg-RX-API-DMAC10.html)
RU2015120556A (ru) Ингибиторы гликозидаз и их применения
JP2014515349A5 (cg-RX-API-DMAC10.html)
JP2015516429A5 (cg-RX-API-DMAC10.html)
JP2020535165A5 (cg-RX-API-DMAC10.html)
JP2020500215A5 (cg-RX-API-DMAC10.html)
JP2024517678A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
JP2024517498A5 (cg-RX-API-DMAC10.html)
JP2022533939A5 (cg-RX-API-DMAC10.html)
JP2022507805A5 (cg-RX-API-DMAC10.html)
JP2023515576A5 (cg-RX-API-DMAC10.html)
JP2024534572A5 (cg-RX-API-DMAC10.html)
JP2020505398A5 (cg-RX-API-DMAC10.html)